TVTXNGMHealthcare·Biotechnology#77 in industry

Travere Therapeutics, Inc.

Reports in 4d· 2026-04-30

+36.6% · 90d

$41.04

+0.53 (+1.32%)

News

(1)

April 2026

Apr 6, 20263 weeks agoDEF 14AHealthcare

Travere Therapeutics, Inc. — DEF 14A Filing

TVTXTravere Therapeutics, Inc.

# 🧾 What This Document Is This is a **DEF 14A**, also known as a **Proxy Statement**. Think of it as the official invitation and agenda for Travere Therapeutics' **2026 Annual Meeting of Stockholders**. It's sent to shareholders so they can vote on important company decisions, even if they can't at

Read summaryView on SEC EDGAR

Key Data

Market Cap$3.79B

Open$40.50

Prev Close$40.50

Day Range$40.50 – $41.43

52W Range$13.88 – $43.31

Volume583,673

P/E (TTM)—

EPS$-0.57

Dividend Yield—

Beta0.87

Profit Margin-5.21%

Revenue Growth73.40%

Price Target$49.57(+20.8%)

Next Earnings2026-04-30(4d)

Analyst Ratings

Strong Buy15 analysts

Buy 14Hold 1Sell 0

About

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.

Healthcare · Biotechnology

497 employees

travere.com